(Adds details from statement, background)
BEIJING, Jan 20 (Reuters) - Sinopharm 1099.HK said on
Friday its biotech unit has received regulatory approval for
clinical trials of its mRNA COVID-19 vaccine targeting the
Omicron variant.
The unit, based in the commercial hub of Shanghai, has built
a research and development platform, as well as workshops with
annual production capacity of 2 billion doses of mRNA vaccine,
Sinopharm said.
Sinopharm, now the China distributor of Merck & Co's MRK.N
COVID-19 antiviral treatment molnupiravir, said its biotech unit
received clinical trial approval from the National Medical
Products Administration.
Several homegrown mRNA candidates are being studied in China
but none has been approved for use. Sinopharm unit China
National Biotec Group Co Ltd said it had designed an mRNA
candidate targeting the Omicron variant of the coronavirus.
The news comes a week after Merck's molnupiravir was
launched in the Chinese market. Merck had said Sinopharm was the
only legally authorised distributor of the treatment in China,
sold under the brand name Lagevrio.
(Reporting by Beijing newsroom; Editing by Clarence Fernandez
and Subhranshu Sahu)
((Ella.Cao@thomsonreuters.com;))